https://orcid.org/0000-0003-1967-9829
Citations (30)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Shigekazu Kitamura, Noboru Imai, Yuka Tanji, Akichika Ozeki & Mika Komori. (2023) Lasmiditan in Japanese Patients with Common Migraine Comorbidities or Concomitant Medications: A Post Hoc Safety and Efficacy Analysis from the MONONOFU Study. Journal of Pain Research 16, pages 1725-1738.
Read now
Read now
Masahito Katsuki, Maiko Nanri, Yuki Miyakoshi, Shuto Gobo, Akihito Koh, Shin Kawamura, Senju Tachikawa, Ryo Matsukawa, Kenta Kashiwagi, Mitsuhiro Matsuo & Fuminori Yamagishi. (2023) Headache Education by E-Learning Through Social Networking Services (Social Media). Journal of Healthcare Leadership 15, pages 285-296.
Read now
Read now
Yoichiro Hashimoto, Mika Komori, Yuka Tanji, Akichika Ozeki & Koichi Hirata. (2022) Lasmiditan for single migraine attack in Japanese patients with cardiovascular risk factors: subgroup analysis of a phase 2 randomized placebo-controlled trial. Expert Opinion on Drug Safety 21:12, pages 1495-1503.
Read now
Read now
Articles from other publishers (27)
Stefan Evers, Grazia Dell’Agnello, Diego Novick, H. Saygin Gonderten, Tommaso Panni & Julio Pascual. (2024) Acute Treatment Patterns, Migraine Burden, and Healthcare Resource Use in People With Migraine: Results From the OVERCOME (EU) Observational Study. Pain and Therapy 13:3, pages 589-607.
Crossref
Crossref
Tsubasa Takizawa, Takahiro Kitano, Masahiro Iijima, Kanae Togo & Naohiro Yonemoto. (2024) Treatment patterns and characteristics of patients with migraine: results from a retrospective database study in Japan. The Journal of Headache and Pain 25:1.
Crossref
Crossref
Etsuko Awaki, Takao Takeshima, Yasuhiko Matsumori, Koichi Hirata, Naoki Miyazaki, Ryo Takemura, Satoshi Osaga, Yoshinori Tanizawa & Mika Komori. (2024) Impact of Migraine on Daily Life: Results of the Observational survey of the Epidemiology, Treatment, and Care of Migraine (OVERCOME [Japan]) Study. Neurology and Therapy 13:1, pages 165-182.
Crossref
Crossref
Shigekazu Kitamura, Takao Takeshima, Daishi Yui, Gabriel Paiva da Silva Lima, Reija Koukakis, Cheng Peng, Ryuji Yoshida, Yotaro Numachi & Miki Hasebe. (2023) Efficacy of Erenumab for Migraine Prevention in Japanese Patients with Episodic and Chronic Migraine: Results of a Post-Hoc Pooled Analysis. Neurology and Therapy 12:6, pages 1993-2006.
Crossref
Crossref
Mamoru Shibata, Atsuko Nihira, Yuka Tanji, Akichika Ozeki, Hideyuki Imagawa & Mika Komori. (2023) Galcanezumab Efficacy Through the Dosing Interval in Japanese Patients with Episodic Migraine: Post Hoc Analysis of a Phase 2 Randomized Trial. Neurology and Therapy 12:6, pages 2007-2019.
Crossref
Crossref
Noboru Imai, Yuki Isogai, Yoshiyuki Shibasaki, Masami Nakai, Miki Ishida, Xiaoping Ning & Nobuyuki Koga. (2023) Effects of Fremanezumab on Medication Overuse in Japanese Chronic Migraine Patients: Post Hoc Analysis of a Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial. Neurology and Therapy 12:6, pages 1981-1991.
Crossref
Crossref
Seung Jae Kim, Hye Jeong Lee, Sue Hyun Lee, Soomi Cho, Kyung Min Kim & Min Kyung Chu. (2023) Most bothersome symptom in migraine and probable migraine: A population-based study. PLOS ONE 18:11, pages e0289729.
Crossref
Crossref
Kentaro Yamato, Hiromi Sano, Koichi Hirata & Takeo Nakayama. (2023) Validation and comparison of the coding algorithms to identify people with migraine using Japanese claims data. Frontiers in Neurology 14.
Crossref
Crossref
Koichi Hirata, Mika Komori, Kaname Ueda, Anthony J. Zagar, Yongin Kim, Dena H. Jaffe, Yasuhiko Matsumori & Takao Takeshima. (2023) Outcomes and Factors Associated with Insufficient Effectiveness of Acute Treatments of Migraine in Japan: Results of the ObserVational survey of the Epidemiology, tReatment, and Care Of MigrainE (OVERCOME [Japan]) Study. Drugs - Real World Outcomes 10:3, pages 415-428.
Crossref
Crossref
Shiori Sasaki, Masahito Katsuki, Junko Kawahara, Chinami Yamagishi, Akihito Koh, Shin Kawamura, Kenta Kashiwagi, Takashi Ikeda, Tetsuya Goto, Kazuma Kaneko, Naomichi Wada & Fuminori Yamagishi. (2023) Developing an Artificial Intelligence-Based Pediatric and Adolescent Migraine Diagnostic Model. Cureus.
Crossref
Crossref
Yen-Feng Wang, Shuu-Jiun Wang, Yao Hsien Huang, Yung-Tai Chen, Yu-Chun Yen, Ben-Chang Shia, Ching-Wen Tsai, Hoi-Fong Chan, Tommaso Panni & Grazia Dell’Agnello. (2023) Treatment pattern and health care resource utilization for Taiwanese patients with migraine: a population-based study. Frontiers in Neurology 14.
Crossref
Crossref
Koichi Hirata, Takao Takeshima, Fumihiko Sakai, Yotaro Numachi, Ryuji Yoshida, Reija Koukakis, Miki Hasebe, Daishi Yui, Gabriel Paiva da Silva Lima & Sunfa Cheng. (2023) Long-term efficacy and safety of erenumab in Japanese patients with episodic and chronic migraine: results from a 28-week open-label treatment period of a randomised trial. BMJ Open 13:8, pages e068616.
Crossref
Crossref
Julio Pascual, Tommaso Panni, Grazia Dell’Agnello, Saygin Gonderten, Diego Novick & Stefan Evers. (2023) Preventive treatment patterns and treatment satisfaction in migraine: results of the OVERCOME (EU) study. The Journal of Headache and Pain 24:1.
Crossref
Crossref
Aubrey Manack Adams, Dawn C. Buse, Elizabeth Leroux, Michel Lanteri-Minet, Fumihiko Sakai, Manjit S. Matharu, Zaza Katsarava, Michael L. Reed, Kristina Fanning, Katherine Sommer & Richard B. Lipton. (2023) Chronic Migraine Epidemiology and Outcomes – International (CaMEO-I) Study: Methods and multi-country baseline findings for diagnosis rates and care. Cephalalgia 43:6.
Crossref
Crossref
Masahito Katsuki, Tomokazu Shimazu, Shoji Kikui, Daisuke Danno, Junichi Miyahara, Ryusaku Takeshima, Eriko Takeshima, Yuki Shimazu, Takahiro Nakashima, Mitsuhiro Matsuo & Takao Takeshima. (2023) Developing an artificial intelligence-based headache diagnostic model and its utility for non-specialists’ diagnostic accuracy. Cephalalgia 43:5, pages 033310242311569.
Crossref
Crossref
Srujitha Marupuru, Ziyad Almatruk, Marion K. Slack & David R. Axon. (2023) Use of Pharmacological and Non-Pharmacological Strategies by Community-Dwelling Adults to Manage Migraine: A Systematic Review. Clinics and Practice 13:3, pages 553-568.
Crossref
Crossref
Marta Waliszewska-Prosół, Marcin Straburzyński, Ewa K. Czapińska-Ciepiela, Magdalena Nowaczewska, Anna Gryglas-Dworak & Sławomir Budrewicz. (2023) Migraine symptoms, healthcare resources utilization and disease burden in a large Polish migraine cohort. The Journal of Headache and Pain 24:1.
Crossref
Crossref
Jaein Seo, Tommi Tervonen, Kaname Ueda, Dian Zhang, Daisuke Danno & Antje Tockhorn-Heidenreich. (2023) Discrete Choice Experiment to Understand Japanese Patients’ and Physicians’ Preferences for Preventive Treatments for Migraine. Neurology and Therapy 12:2, pages 651-668.
Crossref
Crossref
Masahito Katsuki, Yasuhiko Matsumori, Junko Kawahara, Chinami Yamagishi, Akihito Koh, Shin Kawamura, Kenta Kashiwagi, Tomohiro Kito, Masato Oguri, Shoji Mizuno, Kentaro Nakamura, Katsushi Hayakawa, Osamu Ohta, Noa Kubota, Hina Nakamura, Jun Aoyama, Isamu Yamazaki, Satoshi Mizusawa, Yasuhide Ueki, Maiko Nanri, Yuki Miyakoshi, Shuto Gobo, Akio Entani, Toshiko Yamamoto, Miyako Otake, Takashi Ikeda, Mitsuhiro Matsuo & Fuminori Yamagishi. (2023)
Headache education by leaflet distribution during
COVID
‐19 vaccination and school‐based on‐demand e‐learning: Itoigawa Geopark Headache Awareness Campaign
. Headache: The Journal of Head and Face Pain 63:3, pages 429-440.
Crossref
Crossref
Masahito Katsuki, Kenta Kashiwagi, Shin Kawamura, Senju Tachikawa & Akihito Koh. (2023) Fremanezumab for Migraine Prevention in Japanese Elderly Aged Over 70 Years Old. Cureus.
Crossref
Crossref
Masahito Katsuki, Kenta Kashiwagi, Shin Kawamura & Akihito Koh. (2023) Monoclonal Antibodies Against the Calcitonin Gene-Related Peptide and Its Receptor in Japanese Adolescents With Migraines. Cureus.
Crossref
Crossref
Masakazu Ishii, Hirotaka Katoh, Tamotsu Kijima & Ikumi Ito. (2023) The Current State of Headache Treatment and the Involvement of Pharmacists in Treatment of People with Chronic Headache. BPB Reports 6:6, pages 229-235.
Crossref
Crossref
Ido Peles, Mohnnad Asla, Mariya Abayev, Michal Gordon, Victor Novack, Rinat Ribalov, Tamar Lengil, Ron Maor, Mayera Elizur & Gal Ifergane. (2022) Migraine epidemiology and comorbidities in Southern Israel: a clinical database study in a universal health coverage setting. The Journal of Headache and Pain 23:1.
Crossref
Crossref
Masahito Katsuki. (2022) The First Case Series From Japan of Primary Headache Patients Treated by Completely Online Telemedicine. Cureus.
Crossref
Crossref
Takao Takeshima, Kaname Ueda, Mika Komori, Anthony J. Zagar, Yongin Kim, Dena H. Jaffe, Yasuhiko Matsumori & Koichi Hirata. (2022) Potential Unmet Needs in Acute Treatment of Migraine in Japan: Results of the OVERCOME (Japan) Study. Advances in Therapy 39:11, pages 5176-5190.
Crossref
Crossref
Takao Takeshima, Mika Komori, Yuka Tanji, Akichika Ozeki & Yoshihisa Tatsuoka. (2022) Efficacy of Lasmiditan Across Patient and Migraine Characteristics in Japanese Patients with Migraine: A Secondary Analysis of the MONONOFU Trial. Advances in Therapy.
Crossref
Crossref
Yasuhiko Matsumori, Kaname Ueda, Mika Komori, Anthony J. Zagar, Yongin Kim, Dena H. Jaffe, Takao Takeshima & Koichi Hirata. (2021) Burden of Migraine in Japan: Results of the ObserVational Survey of the Epidemiology, tReatment, and Care Of MigrainE (OVERCOME [Japan]) Study. Neurology and Therapy 11:1, pages 205-222.
Crossref
Crossref